653
edits
Difference between revisions of "Invasive breast cancer"
Jump to navigation
Jump to search
→Breast IHC
| Line 161: | Line 161: | ||
**Not derived from myoepithelial cells, merely express a phenotype more in keeping with basal cells than ductal cells | **Not derived from myoepithelial cells, merely express a phenotype more in keeping with basal cells than ductal cells | ||
**Most triple negative (ER, PgR, Her-2); therefore cannot be treated with the usual therapeutic agents | **Most triple negative (ER, PgR, Her-2); therefore cannot be treated with the usual therapeutic agents | ||
**There is an association in young women between basal-like breast cancer and | **There is an association in young women between basal-like breast cancer and BRCA1 mutation. | ||
**Increased incidence in some populations - African-Americans, young women | **Increased incidence in some populations - African-Americans, young women | ||
**Sporadic basal-like cancers do not have a | **Sporadic basal-like cancers do not have a BRCA1 mutation but may have a dysfunctional BRCA1 pathway. | ||
*This molecular group includes a variety of morphologic phenotypes including: | *This molecular group includes a variety of morphologic phenotypes including: | ||